Rectal Cancer Management
For locally advanced rectal cancer (T3-4 or node-positive disease), total neoadjuvant therapy (TNT) with long-course chemoradiation followed by chemotherapy should be offered as the preferred approach, followed by total mesorectal excision (TME) surgery—or watch-and-wait nonoperative management for patients achieving clinical complete response. 1
Initial Assessment and Risk Stratification
Begin with pelvic MRI with dedicated rectal protocol to assess:
- Tumor location relative to anal verge and sphincter complex
- Mesorectal fascia (MRF) involvement
- Extramural vascular invasion (EMVI)
- Tumor deposits and lymph nodes
- Distance from intersphincteric plane
Test all patients for MSI/MMR status at diagnosis—this fundamentally changes treatment approach 1.
Treatment Algorithm by Stage and Molecular Profile
MSI-H/dMMR Tumors
Immunotherapy is the preferred first-line treatment for MSI-H/dMMR locally advanced rectal cancer 1. These tumors show exceptional sensitivity to checkpoint inhibitors and historically poor response to fluorouracil-based chemotherapy. For patients with contraindications to immunotherapy, proceed with standard pMMR/MSS treatment protocols.
pMMR/MSS Locally Advanced Disease
High-risk features requiring TNT:
- T4 tumors
- Low rectal cancer location
- EMVI or tumor deposits
- Threatened mesorectal fascia or intersphincteric plane
- Inability to perform sphincter-sparing surgery
TNT regimen (preferred): Long-course chemoradiation followed by chemotherapy 1. An alternative sequencing is chemotherapy before radiation therapy.
Alternative for select patients: Neoadjuvant FOLFOX with selective addition of chemoradiation if tumor response is insufficient 1. The PROSPECT trial demonstrated this approach achieved noninferior disease-free survival (HR 0.92) with <2% local recurrence at 5 years, though only 9.1% required selective chemoradiation 1. This option depends on treatment goals and patient circumstances.
Early-Stage Disease (T1-2, Node-Negative)
Endoscopic submucosal dissection is now an option for carefully selected early-stage rectal cancers 2. TME remains standard of care, but local excision may be considered for select pT1 tumors or patients with near/complete clinical response to neoadjuvant therapy 3.
Watch-and-Wait Strategy
For patients achieving clinical complete response (cCR) after neoadjuvant therapy, nonoperative management may be discussed as an alternative to TME 2, 1. This preference may be stronger for patients requiring abdominoperineal resection, given the quality-of-life implications.
Definition of cCR:
- Digital rectal exam: No palpable tumor
- Rectoscopy: No residual tumor material, no erythematous ulcer (scar acceptable)
- MRI: Substantial downsizing with no observable residual tumor or only residual fibrosis with limited signal on diffusion-weighted imaging 1
This represents a major paradigm shift—up to 40% of patients may avoid surgery entirely while maintaining oncological safety 4.
Surgical Approach
When surgery is indicated, TME with adequate mesorectal fascia clearance is mandatory 5, 6. The circumferential resection margin must be assessed and documented. Minimally invasive approaches are acceptable when performed by experienced surgeons 6, 7.
Critical Pitfalls to Avoid
Do not use fluorouracil-based chemotherapy as primary treatment for MSI-H/dMMR tumors—these are historically ineffective in this molecular subtype 1.
Do not proceed directly to surgery for locally advanced disease without neoadjuvant therapy—this increases local recurrence risk and misses opportunities for organ preservation 2, 1.
Do not offer watch-and-wait without rigorous confirmation of cCR using all three modalities (DRE, rectoscopy, MRI) 1.
Quality of Life Considerations
The 2024 NCCN guidelines explicitly emphasize balancing curative-intent therapy with minimal quality-of-life impact, particularly for distal rectal cancers 2. Preservation of bowel function, anal continence, and genitourinary function must be weighed against oncological outcomes. This is why watch-and-wait has gained prominence—it offers equivalent survival for complete responders while preserving the rectum 4.
Multidisciplinary Approach
All treatment decisions require multidisciplinary team discussion involving surgical oncology, medical oncology, radiation oncology, radiology, and pathology 2, 5. The complexity of sequencing multimodality therapy and determining surgical candidacy demands coordinated expertise.